Read more

November 11, 2023
4 min watch
Save

VIDEO: AVD-104 shows stability, GA lesion size reduction in phase 2/3 trial

SAN FRANCISCO — In this Healio Video Perspective from Eyecelerator@AAO, Mohamed Genead, MD, CEO of Aviceda Therapeutics, discusses a trial investigating AVD-104 for geographic atrophy secondary to age-related macular degeneration.

The first in-human phase 2/3 SIGLEC trial found that AVD-104 (glycan-coated nanoparticle) was well-tolerated and demonstrated no drug-related serious adverse events after a single injection at baseline. The drug also demonstrated stability and regression in GA lesion size, Genead said.

The FDA cleared an investigational new drug application for AVD-104 for GA treatment earlier this year.